JP2006505564A - Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療 - Google Patents

Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療 Download PDF

Info

Publication number
JP2006505564A
JP2006505564A JP2004544891A JP2004544891A JP2006505564A JP 2006505564 A JP2006505564 A JP 2006505564A JP 2004544891 A JP2004544891 A JP 2004544891A JP 2004544891 A JP2004544891 A JP 2004544891A JP 2006505564 A JP2006505564 A JP 2006505564A
Authority
JP
Japan
Prior art keywords
sarm
nhcor
compound
conhr
snr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004544891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006505564A5 (enExample
Inventor
ダルトン、ジェームズ・ティー
ミラー、デュアン・ディー
ステイナー、ミッチェル・エス
ベベルカ、カレン・エイ
Original Assignee
ジーティーエックス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジーティーエックス・インコーポレイテッド filed Critical ジーティーエックス・インコーポレイテッド
Publication of JP2006505564A publication Critical patent/JP2006505564A/ja
Publication of JP2006505564A5 publication Critical patent/JP2006505564A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
JP2004544891A 2002-10-16 2003-10-14 Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療 Pending JP2006505564A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41833602P 2002-10-16 2002-10-16
PCT/US2003/032513 WO2004035739A2 (en) 2002-10-16 2003-10-14 Treating androgen decline in aging male (adam)-associated conditions with sarms

Publications (2)

Publication Number Publication Date
JP2006505564A true JP2006505564A (ja) 2006-02-16
JP2006505564A5 JP2006505564A5 (enExample) 2006-08-17

Family

ID=32107914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004544891A Pending JP2006505564A (ja) 2002-10-16 2003-10-14 Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療

Country Status (9)

Country Link
US (1) US20050080054A1 (enExample)
EP (1) EP1558233A2 (enExample)
JP (1) JP2006505564A (enExample)
CN (1) CN1726020A (enExample)
AU (1) AU2003287079A1 (enExample)
CA (1) CA2501874A1 (enExample)
IL (1) IL168046A0 (enExample)
TW (1) TW200502250A (enExample)
WO (1) WO2004035739A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508386A (ja) * 2003-10-14 2007-04-05 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体調節剤による骨関連疾患の治療
JP2007520425A (ja) * 2003-06-27 2007-07-26 オリオン コーポレーション アンドロゲン受容体モジュレーターとして有用なプロピオンアミド誘導体
US10203361B2 (en) 2012-06-29 2019-02-12 Keysight Technologies, Inc. Method and apparatus for electrical impedance measurements

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
ATE485300T1 (de) 2004-07-16 2010-11-15 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US8791158B2 (en) 2010-01-11 2014-07-29 Gtx, Inc. Methods of treating meibomian gland dysfunction
CN107405353B (zh) 2014-10-22 2021-07-30 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
SG11201803260PA (en) 2015-10-22 2018-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
JP2022535827A (ja) 2019-06-03 2022-08-10 ハバ セラピューティクス ピーティワイ エルティディ アンドロゲン剤およびアロマターゼ阻害剤の送達のための医薬製剤およびシステム、ならびに使用のための方法
WO2025102293A1 (zh) * 2023-11-16 2025-05-22 北京脑科学与类脑研究所 神经活性雄激素受体调节剂及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) * 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) * 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) * 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
LU88769I2 (fr) * 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5609849A (en) * 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
WO1998053826A1 (en) * 1997-05-30 1998-12-03 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
AU7723198A (en) * 1997-06-04 1998-12-21 University Of Tennessee Research Corporation, The Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US8008348B2 (en) * 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
AU2001285230C1 (en) * 2000-08-24 2008-03-13 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
IL154425A0 (en) * 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
IL162340A0 (en) * 2001-12-06 2005-11-20 Gtx Inc Treating muscle wasting with selective androgen receptor modulators
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
DK1480634T3 (da) * 2002-02-07 2011-11-14 Univ Tennessee Res Foundation Selektive androgenreceptormodulatorer (SARM) til behandling af benign prostatahyperplasi
WO2004034978A2 (en) * 2002-10-15 2004-04-29 Gtx, Inc. Treating obesity with selective androgen receptor modulators
CA2514024A1 (en) * 2003-01-22 2004-08-05 Gtx Inc. Treating androgen deficiency in female (adif)-associated conditions with sarms
MXPA06002462A (es) * 2003-10-14 2006-06-20 Gtx Inc Tratamiento de desordenes relacionados con huesos con moduladores del receptor de angrogeno selectivo.
EP1931199A4 (en) * 2005-08-31 2009-07-29 Univ Tennessee Res Foundation COMBATING NURSE DISEASE, BURNS, WOUNDS AND BACKMARK INJURIES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007520425A (ja) * 2003-06-27 2007-07-26 オリオン コーポレーション アンドロゲン受容体モジュレーターとして有用なプロピオンアミド誘導体
JP4809764B2 (ja) * 2003-06-27 2011-11-09 オリオン コーポレーション アンドロゲン受容体モジュレーターとして有用なプロピオンアミド誘導体
JP2007508386A (ja) * 2003-10-14 2007-04-05 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体調節剤による骨関連疾患の治療
US10203361B2 (en) 2012-06-29 2019-02-12 Keysight Technologies, Inc. Method and apparatus for electrical impedance measurements

Also Published As

Publication number Publication date
EP1558233A2 (en) 2005-08-03
CN1726020A (zh) 2006-01-25
TW200502250A (en) 2005-01-16
IL168046A0 (en) 2009-02-11
WO2004035739A2 (en) 2004-04-29
CA2501874A1 (en) 2004-04-29
AU2003287079A1 (en) 2004-05-04
WO2004035739A3 (en) 2004-09-30
US20050080054A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
KR101088352B1 (ko) 다치환된 선택적 안드로겐 수용체 조절자 및 이를 사용하는 방법
JP4764719B2 (ja) ハロゲン化選択的アンドロゲン受容体調節剤及びその使用方法
JP2006516286A (ja) Ｓａｒｍによる女性のアンドロゲン減少に関連する病気の治療
JP2006506369A (ja) メチレン架橋選択的アンドロゲン受容体調節剤及びその使用方法
JP2006505563A (ja) 選択的アンドロゲン受容体調節剤による肥満治療
US9493403B2 (en) Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
JP2006505564A (ja) Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療
JP2005529952A (ja) Ｎ架橋選択的アンドロゲン受容体修飾物質及びその使用方法
CN104754939A (zh) 用选择性雄激素受体调节剂(sarm)治疗雄激素受体(ar)阳性乳癌的方法
JP2010280733A (ja) 選択的アンドロゲン受容体調節剤による骨関連疾患の治療
EA018699B1 (ru) Применение соединения селективного модулятора андрогеновых рецепторов
EA013818B1 (ru) Полизамещённые селективные модуляторы рецептора андрогенов и способы их применения
JP2005519111A (ja) 不可逆型選択的アンドロゲンレセプタ修飾因子及びその使用方法
US20060276539A1 (en) Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
CN100586954C (zh) 用选择性雄激素受体调节剂治疗骨相关病症

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090915

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100223